Active Biotech: FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. "The
Hans Kolam Loncode Institute Erasmus University Medical Center Drug Administration Lund May Nasdaq Stockholm
Source: finanznachrichten.de